Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Total Liabilities (2021 - 2025)

Prime Medicine (PRME) has disclosed Total Liabilities for 5 consecutive years, with $221.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 53.69% year-over-year to $221.9 million, compared with a TTM value of $221.9 million through Dec 2025, up 53.69%, and an annual FY2025 reading of $221.9 million, up 53.69% over the prior year.
  • Total Liabilities was $221.9 million for Q4 2025 at Prime Medicine, down from $223.2 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $458.1 million in Q4 2021 and bottomed at $38.1 million in Q1 2023.
  • Average Total Liabilities over 5 years is $138.3 million, with a median of $118.8 million recorded in 2021.
  • The sharpest move saw Total Liabilities crashed 90.39% in 2022, then soared 245.63% in 2025.
  • Year by year, Total Liabilities stood at $458.1 million in 2021, then plummeted by 90.39% to $44.0 million in 2022, then soared by 38.0% to $60.8 million in 2023, then soared by 137.51% to $144.4 million in 2024, then soared by 53.69% to $221.9 million in 2025.
  • Business Quant data shows Total Liabilities for PRME at $221.9 million in Q4 2025, $223.2 million in Q3 2025, and $218.1 million in Q2 2025.